NIH Attempts to Revive Diarrhea Vaccine
Rotavirus shot was pulled off the market 5 years ago
<<< Back to Vaccines
By Associated Press
May 4, 2004, 5:47 PM EDT
WASHINGTON -- The National Institutes of Health is attempting to revive an
anti-diarrhea vaccine that was pulled off the market five years ago after a
life-threatening side effect struck some babies.
At issue is rotavirus, an intestinal infection that kills 600,000 children
worldwide each year. In the United States, 3 million children get rotavirus
annually, but good medical care ensures only about 40 of them die. In
developing countries, however, about one child in every 250 dies of
rotavirus.
The first vaccine, called RotaShield, was pulled off the market by its
manufacturer in 1999 after 20 U.S. infants, of the almost 1 million
vaccinated, suffered a life-threatening bowel obstruction.
Health authorities deemed the rare side effect too risky for Americans
because rotavirus is seldom lethal here. Some developing countries, though,
complained that the vaccine could have saved at least 100 of their
children's lives for every case of the bowel problem.
NIH scientists, who created RotaShield, announced Tuesday they have licensed
it to another manufacturer -- BIOVIRx of Minneapolis -- that will attempt to
sell it again.
First use probably will be abroad, said NIH's Michael Mowatt. But company
president Leonard Ruiz said he planned to meet simultaneously with the U.S.
Food and Drug Administration and foreign drug regulators, in hopes of
marketing globally.
Here, a comeback may be tough: Scientists have been testing new rotavirus
vaccine candidates designed to avoid the bowel side effect, but have found
parents and pediatricians somewhat reluctant to try them.
There is scientific disagreement about the side effect. The Centers for
Disease Control and Prevention has estimated the risk of the bowel
obstruction, called intussusception, at one in 10,000 vaccine recipients.
The NIH said Tuesday that recent studies suggest it's more rare, and Ruiz
contended there's no risk when the vaccine is used at the appropriate age.
Back to top of Document